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Background: Visual dysfunction is common in Parkinson’s disease (PD). It remains, however, unknown whether it is
related to structural alterations of the retina. The aim of this study is to compare visual field (VF) findings and
circumpapillary retinal nerve fiber layer (RNFL) thickness in a series of PD patients and normal controls, in order to
assess possible retinal anatomical changes and/or functional damage associated with PD.
Methods: PD patients and controls were recruited and underwent VF testing with static automated perimetry and
RNFL examination with optical coherence tomography (OCT). Cognitive performance using Mini Mental State
Examination (MMSE), PD staging using modified Hoehn and Yahr (H-Y) scale and duration of the disease was
recorded in PD patients.
Results: One randomly selected eye from each of 24 patients and 24 age-matched controls was included. OCT
RNFL thickness analysis revealed no difference in the inferior, superior, nasal or temporal sectors between the
groups. The average peripapillary RNFL was also similar in the two groups. However, perimetric indices of
generalized sensitivity loss (mean deviation) and localized scotomas (pattern standard deviation) were worse in
patients with PD compared to controls (p < 0.01). 73% of eyes of PD patients had glaucomatous-like asymmetrical
hemifield defects with abnormal Glaucoma Hemifield Test and various combinations of arcuate defects (n = 12),
nasal steps (n = 11) and paracentral scotomas (n = 16). Bilateral defects were found in 14 patients (58%). No
correlation was found between VF indices and MMSE or H-Y scores.
Conclusion: PD patients may demonstrate glaucomatous-like perimetric defects even in the absence of decreased
RNFL thickness.
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Parkinson’s disease (PD) is a neurodegenerative disorder
characterized by selective loss of dopaminergic neurons
in the nigrostriatal pathway. PD patients experience pro-
gressive motor impairment, often accompanied by a var-
iety of non-motor symptoms [1]. Visual dysfunction is
common in PD and manifests as visual acuity loss,
reduced colour discrimination and deficiencies in visual
contrast sensitivity and motion perception [2-6]. These
visual deficits may stem from dopaminergic denervation
of amacrine retinal cells [6,7]. Dopamine is essential for* Correspondence: e_tsironi@hotmail.com
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reproduction in any medium, provided the orlight adaptation, by facilitating visual signal transmission
in rod and cone circuits, and exerts multiple trophic
effects in retinal cells [7]. Studies in autopsy cases of PD
revealed loss of the dopaminergic innervation around
the fovea and decreased retinal dopamine concentration
despite the preservation of retinal dopaminergic neurons
[8,9]. It remains, however, unknown whether these
changes could result in structural alterations of the ret-
ina or only in functional deficits.
In a search of a potential biomarker of PD progression
or response to neuroprotective agents, a number of
studies [10-12] using optical coherence tomography
(OCT), a non-invasive imaging modality [13], have pro-
vided evidence of peripapillary retinal nerve fiber layer
(RNFL) thinning in PD patients. However, recent studiesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the retina around the optic nerve head in PD patients
[14-16]. On the contrary, visual function tests have high-
lighted differences between PD patients and controls [6].
A previous study has shown characteristic visual field
(VF) defects in PD patients [17].
In the present study, in order to investigate both ret-
inal anatomical changes and functional damage in PD,
we compared RNFL thickness measured with OCT and
VFs performed with static automated perimetry in a
series of PD patients and normal controls.Methods
Patients
This cross-sectional case–control study was conducted
at the University Eye Clinic of Larissa, Greece, be-
tween June 2009 and June 2010. Patients diagnosed
with PD attending the University Neurology Clinic of
Larissa, Greece, were referred for ophthalmic evalu-
ation in the University Ophthalmology Department.
Patients were recruited in a consecutive-if-eligible
fashion. All patients in our sample underwent a neuro-
logic examination. Eligible patients met the criteria for
PD [18] including substantial and sustained response
to L-dopa, and were under stable and optimal treat-
ment with L-dopa. In addition, all patients were re-
ceiving treatment and were in “ON” period during the
ophthalmic evaluation. The patients’ duration of PD,
general medical history and treatment modalities were
recorded. PD staging was assessed with the modified
Hoehn and Yahn (H-Y) scale and severity of cognitive
impairment was evaluated using the Mini Mental State
Examination (MMSE) test. Age- and gender-matched
individuals attending the outpatient eye clinic for mild
cataracts or refraction problems were recruited as
controls.
Inclusion criteria for PD patients and controls were:
visual acuity equal to or better than 6/10, spherical
equivalent refractive error between −5 and +3 diopters,
at least two intraocular pressure (IOP) readings lower
than 21 mmHg at two different time points, and ability
to follow the study protocol. In an effort to avoid con-
founding conditions, exclusion criteria were: presence
of diabetic retinopathy, presence of other neurodegen-
erative disorders, positive family history of glaucoma,
narrow anterior chamber angles at gonioscopy, cup-to-
disc ratio greater than 0.6, glaucomatous appearance of
the optic discs (defined as fellow eye asymmetry in
cup-to-disc ratio > 0.2, neuroretinal rim thinning, disc
hemorrhages or retinal nerve fiber layer defects), signs
of ocular disease other than visually non-significant
cataract, and previous ocular surgery other than un-
eventful phacoemulsification.Procedures
Both PD patients and controls underwent a thorough
ophthalmic evaluation, including assessment of best-
corrected visual acuity, VF testing, Goldmann applana-
tion tonometry, slit lamp examination, gonioscopy and
dilated fundoscopy with a 90 diopters lens. Standard
automated perimetry was performed in all patients with
the Humphrey 24–2 SITA-Standard algorithm on the
day of examination and was repeated after a period of
up to two weeks. RNFL OCT scans were obtained in all
participants after pupil dilation in the first visit, using
the Stratus OCT (Carl Zeiss Meditec, Dublin, CA, USA)
and analyzed with the fast RNFL algorithm. Only partici-
pants with high quality OCT scans (signal strength ≥7)
and no artifacts were included.
To be eligible for analysis, participants had to have a
reliable second VF (false positive and false negative
responses lower than 33% and fixation losses lower than
20%). Mean deviation (MD) and pattern standard devi-
ation (PSD) were used as perimetric indices of general-
ized sensitivity loss and localized scotomas respectively.
Only data from the second VF entered the statistical
analysis. Based on reports about scotomas similar to
glaucomatous visual field losses in PD patients [17], in
addition to the Humphrey-provided MD and PSD indi-
ces, we calculated sensitivity scores over the superior
and inferior hemifields. The VF printout was used for
the calculation of mean sensitivity scores in the superior
(Mean Sensitivity Superior-MSS) and inferior hemifield
(Mean Sensitivity Inferior-MSI) from the individual test-
point sensitivity values in the corresponding hemifield.
The Glaucoma Hemifield Test (GHT) results, as an
index of asymmetry between sensitivity losses in the su-
perior and inferior hemifield of each eye were also ana-
lyzed. A scotoma was defined as a cluster of at least
three abnormal points (including two or more points
depressed by a p-value less than 0.5%) on the pattern
deviation probability map of the Humphrey 24–2
SITA-Standard programme. Points with decreased sen-
sitivity immediately adjacent to the blind spot were not
considered parts of scotomas. Test points at the periph-
ery (rim points) could be considered as parts of scot-
omas if at least two of the points were non-peripheral
(nonrim) [19].
The study protocol adhered to the tenets of the Hel-
sinki Declaration and was approved by the Institutional
Board of the University Hospital of Larissa, Greece. All
participants gave informed consent before entering the
study.
Statistical analysis
Both eyes from each patient were examined. With the
exception of the VF asymmetry analysis in PD patients,
one randomly selected eye from each participant was
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as mean ± standard deviation (SD). Normality of distri-
bution was assessed with the Kolmogorov-Smirnov test.
The independent samples t-test was used in comparisons
of normally distributed data. Mann–Whitney testing was
used for non-parametric comparisons. The chi-square
test was used to compare differences between groups in
categorical variables. Comparisons between fellow eyes
or between superior and inferior hemifields of the same
eye were performed with the paired t-test where appro-
priate, or otherwise with the Wilcoxon signed ranks test.
Correlation analysis was performed with the Spearman
test. A p-value below 0.05 was considered significant.
The SPSS software package was used for all analyses
(version 16; SPSS, Inc., Chicago, IL, USA).Results
A sample of 33 PD patients was initially recruited, with
nine patients being excluded due to unreliable VFs
(n = 7) or inability to acquire an acceptable OCT scan
(n = 2). Thus, data from 24 PD patients and 24 controls
were analyzed. Mean (SD) age was 66.6 (10.2) years in
PD patients and 64.3 (7.3) years in the control group
(p = 0.374). Mean disease duration, H-Y staging and
MMSE score in the PD group were 5.3 (3.5) years, 1.9
(0.6) and 28.3 (2.4), respectively. Mean IOP was 15.3
(2.2) mmHg in the PD and 14.5 (2.6) mmHg in the con-
trol group (p = 0.241). Patients’ characteristics are dis-
played in Table 1 and Additional file 1.
Analysis of the OCT parameters revealed no difference
between the groups in mean RNFL thickness in the in-
ferior, superior, nasal and temporal sectors of the retina
(Table 2).
Reliable VFs were obtained from 48 eyes of 24 PD
patients. MD and PSD scores were worse in PD patients
compared to the control group (p < 0.05, Table 2). Like-
wise, MSI and MSS were found to be lower in PD
patients, compared to controls (p < 0.01, Table 2). In the
PD group, mean MSS was 22.17 (5.84) dB and mean
MSI was 23.95 (4.30) dB. MSI was higher compared to
MSS (p = 0.014, Wilcoxon signed ranks test).Table 1 Characteristics of the study groups. Results
presented as mean (standard deviation)
PD group Control group p-value
Age (years) 66.6 (10.2) 64.3 (7.3) 0.3741
Sex (men/women) 14/10 11/13 0.3862
Right/ Left eye 14/10 13/11 0.7712
Decimal Visual Acuity 0.86 (0.12) 0.83 (0.12) 0.3631
Intraocular Pressure (mmHg) 15.3 (2.2) 14.5 (2.6) 0.2411
PD: Parkinson disease, 1: independent samples t-test, 2: chi-square test.No correlation was found between MD and MMSE
scores (Spearman ρ= 0.313, p = 0.137) or H-Y scale
scores (ρ=−0.229, p = 0.281).
In the group of PD patients, the GHT was within nor-
mal limits in 8 (16.7%) eyes, borderline in 5 (10.4%) eyes
and outside normal limits in 35 (72.9%) eyes. In the
group of patients whose GHT was outside normal limits,
arcuate defects were evident in 12 eyes, nasal steps in 11
eyes, and paracentral scotomas in 16 eyes (Figure 1). Bi-
lateral defects were found in 14 patients. No VF defects
were detected in controls.
Additional analysis was performed to test for asym-
metry in VF indices of fellow eyes. Right and left eyes
were not found to differ for MD and PSD in PD patients
(paired t-test, p = 0.518 and Wilcoxon signed ranks test,
p = 0.440, respectively).
Discussion
The present study did not provide evidence of RNFL
thinning in patients with PD. However, VF defects were
more frequent in PD patients compared to controls.
A number of previous studies [10-12], although not all
[14-16], provided evidence of reduced RNFL thickness
in PD patients. Inzelberg et al. [11] reported a reduction
in the infero temporal RNFL thickness, which was topo-
graphically matched to the VF defects, in a subset of five
patients with reliable VFs. A reduction in average RNFL
thickness, macular thickness and volume was also
reported in another study in PD patients [11]. Decreased
RNFL thickness has also been suggested in PD patients
examined with scanning laser ophthalmoscopy [21].
Moschos et al. [12] reported reduced temporal and infer-
ior RNFL thickness in PD patients compared to controls.
However, in agreement with our results, mean RNFL
thickness did not differ between the groups. In addition,
OCT findings with spectral domain OCT (SD-OCT)
suggest a decreased thickness of the paramacular inner
retina, including the nerve fiber layer, the ganglion cell
layer and the inner plexiform layer in PD patients, while
outer retinal layer thickness was not found to differ from
controls [22]. Increased inner nuclear layer thickness has
been identified in a more recent study [16].
The finding of RNFL thinning in PD patients has been
attributed to the loss of trophic effects induced by dopa-
mine depletion in the retina [7]. Although autopsy stud-
ies have documented decreased retinal dopamine
concentration in PD patients [9], degeneration of retinal
dopaminergic neurons and changes in cell density have
not been shown [8]. It is not obvious how dopamine de-
pletion could mediate RNFL thinning in PD. A pilot
study using the recently introduced SD-OCT imaging
platform did not detect differences in the RNFL thick-
ness of PD patients and controls [14]. Moreover, Archi-
bald et al. failed to detect any RNFL thinning in PD
Table 2 Optical coherence tomography and visual field results [mean (standard deviation)] for the study and
control groups
PD group Control group p-value
OCT parameters Superior average (μm) 116.58 (17.09) 122.05 (18.33) 0.3121
Inferior average (μm) 128.58 (16.12) 127.05 (18.55) 0.7711
Nasal average (μm) 72.38 (18.06) 70.35 (8.90) 0.6501
Temporal average (μm) 68.58 (13.91) 67.10 (12.49) 0.7141
Average thickness (μm) 96.42 (11.13) 96.34 (11.46) 0.9821
Visual field parameters Mean Deviation (dB) −5.71 (4.59) −0.92 (1.99) <0.0011
Pattern Standard Deviation (dB) 4.39 (2.59) 2.26 (0.70) 0.0132
Mean Sensitivity Inferior (dB) 23.95 (4.30) 29.64 (5.81) <0.0012
Mean Sensitivity Superior (dB) 22.17 (5.84) 29.36 (5.74) <0.0012
OCT: Optical coherence tomography.
PD: Parkinson’s disease.
1: Independent samples t-test.
2: Mann Whitney test.
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defects [15]. In another study in PD patients, no evi-
dence of RNFL thinning with the use of SD- OCT was
found [16]. Similarly, in our present study, no signifi-
cant difference was detected in RNFL thickness in PD
patients and controls. Discrepancies between studies
may be attributed to differences in study populations,
small sample size in some reports, different stages of
disease and differences in imaging technologies. In our
study, the widely available time-domain OCT platform
(Stratus OCT) was used. This device is based on low-
coherence interferometry to produce high-resolution,
two-dimensional images of the optic nerve head and
retina [23]. More recently, SD-OCT, with a scanning
speed up to 200 times higher than time-domain OCT
and a higher axial resolution was introduced in clinical
practice [24-26]. Consequently, it could be argued that
SD-OCT would provide more valid data and a greater
discriminating ability than time-domain OCT. However,
despite the theoretical advantages of the superior repro-
ducibility, resolution and higher scanning speed, recent
studies have failed to demonstrate an unequivocal su-
periority of the commercially available SD-OCT devices
over time-domain OCT in the assessment of optic
nerve diseases [27-29]. Therefore, the use of the widely
available Stratus OCT that employs time-domain tech-
nology instead of newer SD-OCT devices may not ne-
cessarily limit the validity of our results.
Compared to structural tests, visual function tests may
be more relevant in detecting differences between PD
patients and controls. Yenice et al. [17] studied VFs in
14 patients with PD, and found decreased MD and PSD
scores compared to the control group. In that study, six
eyes had nasal steps and six eyes had arcuate defects. A
pattern that resembles nerve fiber bundle defects and
glaucomatous-like VF loss was also observed in PDpatients in our study: 73% of 48 eyes had a GHT outside
normal limits, compared to 50% of 28 eyes in the study
by Yenice et al. It should be noted that the GHT is an
algorithm that was specifically developed for glaucoma.
However, we have chosen to analyze GHT results due to
the resemblance of typical glaucomatous VF defects with
the scotomas found in our non-glaucoma cohort of PD
patients. In line with the report by Yenice et al. [17], ar-
cuate defects, nasal steps and paracentral scotomas were
also found in our patients. Bilateral VF damage was
identified in 14 of our patients.
An increased occurrence of probable glaucoma was
reported in a retrospective chart review of 38 patients
with PD [30]. To ensure that our participants did not
have glaucoma, that could confound our results, we
excluded PD patients and controls who had positive
family history of glaucoma, narrow anterior chamber
angles on gonioscopy or optic disc findings suspicious
for glaucoma. Therefore, despite the similarities of glau-
comatous scotomas with the scotomas detected in our
study, it is quite unlikely that the perimetric findings
observed in our patients can be attributed to glaucomat-
ous neuropathy. In glaucoma, there is typically a match-
ing of structural and functional damage. Characteristic
VF defects in glaucoma patients can usually be matched
to topographically corresponding damage of the optic
disc and/or RNFL. The glaucomatous-like visual field
defects observed in our series of non-glaucoma PD
patients, however, could not be matched to correspond-
ing RNFL thinning (Figure 1). Instead, it is reasonable to
assume that the functional deficit observed in this co-
hort of patients can be explained by intra-retinal, sub-
cortical and cortical neuronal disorganization or injury
related to PD.
Animal and human studies have suggested the involve-
ment of the visual pathway in the disease process of PD
Figure 1 A and B: Humphrey visual field (A) and peripapillary retinal nerve fiber layer (RNFL) thickness profile (B) of the left eye of a
67 years-old man with Parkinson’s disease. The visual field print-out shows decreased mean deviation (MD), pathological pattern standard
deviation (PSD), glaucoma hemifield test (GHT) outside normal limits, and deep superior arcuate scotoma. The optical coherence tomography
printout shows that the RNFL thickness is within normal limits. The marginal decrease of RNFL thickness at the superior-temporal area does not
correspond to the visual field scotomas.
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cesses, as well as the retina may be affected [6].
Reduced responses have been reported by means of
pattern electroretinograms (pERG) reflecting ganglion
cell dysfunction [33,34], as well as flash ERG, indicating
outer retina impairment [34]. Multifocal ERG testing,
which is believed to mainly reflect bipolar cell activity
also revealed differences in PD patients and controls
[12]. pERG studies also highlighted changes in retinal
ganglion cell function in PD [34-36]. Increased laten-
cies in visual evoked potentials (VEP) were also found,
corresponding to a delayed response to visual stimuli
due to retinal or post-retinal processing dysfunction
[34,37]. This delayed response could at least in part
originate from retinal damage, given that dopamine
neurons are rare in the visual system at sites other
than the retina [5].
Indeed, the pathophysiological basis of the functional
visual system impairment in PD has not been fully elu-
cidated. A decrease in dopamine concentration has
been found in the retina of patients suffering from PD
[9]. Although the role of dopamine in the retinal neural
circuitry is not fully understood, there is evidence that
dopaminergic deficiency may directly or indirectly affect
amacrine, horizontal and retinal ganglion cells and
modify the receptive field output of the retina [6,31].
These changes in the coupling between the different
cellular systems that form the retinal network could, at
least in part, explain the VF defects observed in the
present study.
L-dopa therapy in PD patients may also have an effect
on visual parameters. Actually, administration of L-dopa
in PD patients was found to transiently reverse contrast
sensitivity abnormalities, pERG alterations and VEP la-
tencies [6,37]. On the contrary, in our sample, VF
defects were identified despite our patients being under
optimal L-Dopa treatment and in “ON” period. This
suggests that apart from dopamine deficiency, there may
also be additional mechanisms accounting for retinal
dysfunction in patients with PD.
It should be noted that fixation problems and motor
system symptoms can also make VF testing a demanding
task for this group of patients. Moreover, it has been
shown that reaction times and saccadic eye movements
may be affected in PD [38], leading to poor VF perform-
ance. However, all patients analyzed in the present study
had reliable VFs. Additionally, the 24–2 SITA-Standard
algorithm that was used offers the advantage of a rela-
tively short testing time compared to other full-
threshold strategies [39]. Another relevant feature of this
algorithm is that it continuously monitors the patient’s
response rate and adjusts the stimulus presentation rate
accordingly [40]. Therefore, motor dysfunction per se
cannot fully explain the worse perimetric performanceof our patients compared to age-matched controls. In
addition, visuo-spatial deficits and dysfunction of the vis-
ual information processing from the retina to the visual
cortex was also reported in PD patients [6] and could
contribute to VF defects. However, in the present study,
PD patients had a mean MMSE score that corresponds
to a normal cognitive function, while 6 patients had a
score under the recently suggested cut-off value [41].
Analysis of the data did not show any correlation be-
tween the MMSE score and VF indices. This finding
may suggest that VF damage in PD patients can be
attributed, at least to a certain extent, to retinal
dysfunction.
Regardless of the underlying pathophysiological mech-
anism, our finding that PD patients can have significant
visual field defects is clinically relevant. Clinicians need
to be aware of the association between this neurodegen-
erative disorder and visual field deficits. In fact, the attri-
bution of “true” glaucomatous VF defects in PD patients
with definite glaucoma can be clinically challenging. In
such cases, as previously discussed, careful attention to
the matching patterns of structural and functional dam-
age would be critical for the assessment of possible glau-
comatous damage. Even more, as judged by the depth
and extent of the scotomas, an appreciable functional
deficit could be anticipated for at least some of these
patients. The impact of these VF defects on the patient’s
quality of life remains to be determined.
Conclusion
The present study provides evidence of perimetric
defects in a group of PD patients without concomitant
signs of anatomical retinal damage. Despite the absence
of morphological evidence of RNFL tissue loss, the pat-
tern of VF defects may resemble retinal ganglion cell
dysfunction. Prospective longitudinal investigations
would be valuable to elucidate retinal structural and
functional changes in the course of the disease.
Additional file
Additional file 1: Clinical characteristics of patients with Parkinson’s
disease.
Abbreviations
PD: Parkinson Disease; VF: Visual Field; OCT: Optical Coherence Tomography;
RNFL: Retinal Nerve Fiber Layer; MD: Mean Deviation; PSD: Pattern Standard
Deviation; IOP: Intraocular Pressure; MMSE: Mini Mental State Examination;
VEP: Visual Evoked Potential; ERG: Electoretinogram; GHT: Glaucoma
Hemifield Test; MSS: Mean Sensitivity Superior; MSI: Mean Sensitivity Inferior.
Competing interests
The authors declare that they have no competing interests.
Authors’ contribution
EET: Study design, revising the manuscript, interpretation of data, study
coordination and supervision AID: Drafting and revising the manuscript,
Tsironi et al. BMC Ophthalmology 2012, 12:54 Page 7 of 7
http://www.biomedcentral.com/1471-2415/12/54interpretation of data, statistical analysis AK: Drafting the manuscript,
interpretation of dataED: Drafting the manuscript, analysis of dataFZ, SV, GP
and SR: Acquisition and analysis of data GMH: Analysis and interpretation of
data, revising the manuscript. All authors read and approved the final
manuscript.
Funding
There was no financial support for this study.
Author details
1Department of Ophthalmology, University Hospital of Larissa, Faculty of
Medicine, University of Thessaly, Mezourlo 41222 Larissa, Greece.
2Department of Neurology, University Hospital of Larissa, Faculty of Medicine,
University of Thessaly, Larissa, Greece.
Received: 27 June 2012 Accepted: 25 September 2012
Published: 2 October 2012
References
1. Chaudhuri KR, Schapira AH: Non-motor symptoms of Parkinson's disease:
dopaminergic pathophysiology and treatment. Lancet Neurol 2009,
8:464–474.
2. Jones RD, Donaldson IM, Timmings PL: Impairment of high-contrast visual
acuity in Parkinson's disease. Mov Disord 1992, 7:232–238.
3. Silva MF, Faria P, Regateiro FS, Forjaz V, Januário C, Freire A, et al:
Independent patterns of damage within magno-, parvo- and
koniocellular pathways in Parkinson's disease. Brain 2005, 128:2260–2271.
4. Bodis-Wollner I, Marx MS, Mitra S, Bobak P, Mylin L, Yahr M: Visual
dysfunction in Parkinson's disease Loss in spatiotemporal contrast
sensitivity. Brain 1987, 110:1675–1698.
5. Armstrong RA: Visual symptoms in Parkinson's disease. Parkinsons Dis
2011, 2011:908306.
6. Archibald NK, Clarke MP, Mosimann UP, Burn DJ: The retina in Parkinson's
disease. Brain 2009, 132:1128–1145.
7. Witkovsky P: Dopamine and retinal function. Doc Ophthalmol 2004,
108:17–40.
8. Nguyen-Legros J: Functional neuroarchitecture of the retina: hypothesis
on the dysfunction of retinal dopaminergic circuitry in Parkinson's
disease. Surg Radiol Anat 1988, 10:137–144.
9. Harnois C, Di Paolo T: Decreased dopamine in the retinas of patients with
Parkinson's disease. Invest Ophthalmol Vis Sci 1990, 31:2473–2475.
10. Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A: Retinal nerve fiber layer
thinning in Parkinson disease. Vision Res 2004, 44:2793–2797.
11. Altintas O, Işeri P, Ozkan B, Cağlar Y: Correlation between retinal
morphological and functional findings and clinical severity in Parkinson's
disease. Doc Ophthalmol 2008, 116:137–146.
12. Moschos MM, Tagaris G, Markopoulos I, Margetis I, Tsapakis S, Kanakis M,
et al: Morphologic changes and functional retinal impairment in patients
with Parkinson disease without visual loss. Eur J Ophthalmol 2011,
21:24–29.
13. Swanson EA, Izatt JA, Hee MR, Huang D, Lin CP, Schuman JS, et al: In vivo
retinal imaging by optical coherence tomography. Opt Lett 1993,
18:1864–1866.
14. Aaker GD, Myung JS, Ehrlich JR, Mohammed M, Henchcliffe C, Kiss S:
Detection of retinal changes in Parkinson's disease with spectral-domain
optical coherence tomography. Clin Ophthalmol 2010,
4:1427–1432.
15. Archibald NK, Clarke MP, Mosimann UP, Burn DJ: Retinal thickness in
Parkinson's disease. Parkinsonism Relat Disord 2011, 17:431–436.
16. Albrecht P, Müller AK, Südmeyer M, Ferrea S, Ringelstein M, Cohn E, et al:
Optical coherence tomography in parkinsonian syndromes. PLoS One
2012, 7(4):34891. Epub 2012 Apr 13.
17. Yenice O, Onal S, Midi I, Ozcan E, Temel A, I-Gunal D: Visual field analysis
in patients with Parkinson's disease. Parkinsonism Relat Disord 2008,
14:193–198.
18. Gelb DJ, Oliver E, Gilman S: Diagnostic criteria for Parkinson disease. Arch
Neurol 1999, 56:33–39.
19. Goldberg I, Graham SL, Klistorner AI: Multifocal objective perimetry in the
detection of glaucomatous field loss. Am J Ophthalmol 2002, 133:29–39.
20. Murdoch IE, Morris SS, Cousens SN: People and eyes: statistical
approaches in ophthalmology. Br J Ophthalmol 1998, 82:971–973.21. Yavas GF, Yilmaz O, Küsbeci T, Oztürk F: The effect of levodopa and
dopamine agonists on optic nerve head in Parkinson disease. Eur J
Ophthalmol 2007, 17:812–816.
22. Hajee ME, March WF, Lazzaro DR, Wolintz AH, Shrier EM, Glazman S, et al:
Inner retinal layer thinning in Parkinson disease. Arch Ophthalmol 2009,
127:737–741.
23. Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, et al:
Optical coherence tomography. Science 1991, 254:1178–1181.
24. Sung KR, Kim JS, Wollstein G, Folio L, Kook MS, Schuman JS: Imaging of the
retinal nerve fibre layer with spectral domain optical coherence
tomography for glaucoma diagnosis. Br J Ophthalmol 2011, 95:909–914.
25. Wojtkowski M, Srinivasan V, Fujimoto JG, Ko T, Schuman JS, Kowalczyk A, et al:
Three-dimensional retinal imaging with high-speed ultrahigh-resolution
optical coherence tomography. Ophthalmology 2005, 112:1734–1746.
26. Nassif N, Cense B, Park BH, Yun SH, Chen TC, Bouma BE, et al: In vivo
human retinal imaging by ultrahigh-speed spectral domain optical
coherence tomography. Opt Lett 2004, 29:480–482.
27. Sehi M, Grewal DS, Sheets CW, Greenfield DS: Diagnostic ability of Fourier-
domain vs time-domain optical coherence tomography for glaucoma
detection. Am J Ophthalmol 2009, 148:597–605.
28. Chang RT, Knight OJ, Feuer WJ, Budenz DL: Sensitivity and specificity of time-
domain versus spectral-domain optical coherence tomography in diagnosing
early to moderate glaucoma. Ophthalmology 2009, 116:2294–2299.
29. Moreno-Montanes J, Olmo N, Alvarez A, Garcia N, Zarranz-Ventura J: Cirrus
high-definition optical coherence tomography compared with Stratus
optical coherence tomography in glaucoma diagnosis. Invest Ophthalmol
Vis Sci 2010, 51:335–343.
30. Bayer AU, Keller ON, Ferrari F, Maag KP: Association of glaucoma with
neurodegenerative diseases with apoptotic cell death: Alzheimer's
disease and Parkinson's disease. Am J Ophthalmol 2002, 133:135–137.
31. Bodis-Wollner I: Visual deficits related to dopamine deficiency in
experimental animals and Parkinson's disease patients. Trends Neurosci
1990, 13:296–302.
32. Djamgoz MB, Hankins MW, Hirano J, Archer SN: Neurobiology of retinal
dopamine in relation to degenerative states of the tissue. Vision Res 1997,
37:3509–3529.
33. Peppe A, Stanzione P, Pierelli F, De Angelis D, Pierantozzi M, Bernardi G: Visual
alterations in de novo Parkinson's disease: pattern electroretinogram
latencies are more delayed and more reversible by levodopa than are
visual evoked potentials. Neurology 1995, 45:1144–1148.
34. Gottlob I, Schneider E, Heider W, Skrandies W: Alteration of visual evoked
potentials and electroretinograms in Parkinson's disease. Electroencephalogr
Clin Neurophysiol 1987, 66:349–357.
35. Langheinrich T, Elst L, Tebartz V, Lagrèze WA, Bach M, Lücking CH, et al:
Visual contrast response functions in Parkinson's disease: evidence from
electroretinograms, visually evoked potentials and psychophysics. Clin
Neurophysiol 2000, 111:66–74.
36. Nightingale S, Mitchell KW, Howe JW: Visual evoked cortical potentials
and pattern electroretinograms in Parkinson's disease and control
subjects. J Neurol Neurosurg Psychiatry 1986, 49:1280–1287.
37. Bodis-Wollner I, Yahr MD: Measurements of visual evoked potentials in
Parkinson's disease. Brain 1978, 101:661–671.
38. Shibasaki H, Tsuji S, Kuroiwa Y: Oculomotor abnormalities in Parkinson's
disease. Arch Neurol 1979, 36:360–364.
39. Wild JM, Pacey IE, Hancock SA, Cunliffe IA: Between-algorithm, between-
individual differences in normal perimetric sensitivity: full threshold,
FASTPAC, and SITA. Swedish Interactive Threshold algorithm. Invest
Ophthalmol Vis Sci 1999, 40:1152–1161.
40. Bengtsson B, Olsson J, Heijl A, Rootzén H: A new generation of algorithms
for computerized threshold perimetry, SITA. Acta Ophthalmol Scand 1997,
75:368–375.
41. Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C,
Crucian GP, et al: The MoCA: well-suited screen for cognitive impairment
in Parkinson disease. Neurology 2010, 9(75):1717–1725.
doi:10.1186/1471-2415-12-54
Cite this article as: Tsironi et al.: Perimetric and retinal nerve fiber layer
findings in patients with Parkinson’s disease. BMC Ophthalmology 2012
12:54.
